For more than 20 years emepronium bromide has been used in the treatment of urgency and urge incontinence. Different dosages have been used and several studies made, but a real double-blind controlled study has never been performed in patients with the same urodynamic findings. Two studies have been carried out: (A) A double-blind controlled crossover clinical trial, estimating the effect of emepronium bromide 200 t.i.d. against 100 mg t.i.d. and one placebo. (B) An open clinical trial where urodynamic parameters were combined under treatment with emepronium bromide in the two doses mentioned. Renal and liver function was also tested and finally the level of the drug in serum was determined. The results of investigation A showed: (1) the patients (statistically significant) preferred the effect of the emepronium medication, 200 mg t.i.d., whereas it was impossible to separate the effect of 100 mg t.i.d. from the placebo effect, and (2) the result was in accordance with the reduction of frequency of micturition, which dereased significantly with 10–20%. The results of investigation B showed: (1) no increase of residual urine; (2) the total volume at first bladder contraction has statistically increased in patients with detrusor hyperreflexia; (3) bladder capacity was increased in patients with left-shift cystometrograms; (4) the urethral closure pressure profile showed no changes under medication; (5) renal and liver function was not influenced by emepronium, and (6) a minimum concentration of emepronium in serum – about 20–30 µg/l – is necessary to give a satisfactory effect on the bladder. This level is only reached under treatment with emepronium bromide 200 mg t.i.d.

Keywords:
Emepronium bromide (Cetiprin), Detrusor hyperreflexia, urge incontinence, Cystometric and UCPP studies, Multiple sclerosis
This content is only available via PDF.
© 1978 S. Karger AG, Basel
1978
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.